Reset filter
Mots-clés
Neoplasia ×
Afficher plus Mots-clés
Table des matières
  1. 1. Essai clinique
  2. 2. Routinedokumentation
  3. 3. Études de registres/cohortes
  4. 4. Assurance qualité
  5. 5. Standard de données
  6. 6. Questionnaire pour les patients
  7. 7. Spécialité médicale
    1. 7.1. Anesthésie
    1. 7.2. Dermatologie
    1. 7.3. HNO
    1. 7.4. Gériatrie
    1. 7.5. Gynécologie/obstétrique
    1. 7.6. Médecine interne
      1. Hématologie
      1. Infectiologie
      1. Cardiologie/angiologie
      1. Pneumologie
      1. Gastroentérologie
      1. Néphrologie
      1. Endocrinologie/métabolisme
      1. Rhumatologie
    1. 7.7. Neurologie
    1. 7.8. Ophtalmologie
    1. 7.9. Médecine palliative
    1. 7.10. Pathologie/médécine légale
    1. 7.11. Pédiatrie
    1. 7.12. Psychiatrie/psychosomatique
    1. 7.13. Radiologie
    1. 7.14. Chirurgie
      1. Chirurgie générale/viscérale
      1. Neurochirurgie
      1. Chirurgie plastique
      1. Chirurgie cardiaque/thoracique
      1. Chirurgie traumatologique/orthopédie
      1. Chirurgie vasculaire
    1. 7.15. Urologie
    1. 7.16. Médecine dentaire/MKG
Modèles de données sélectionnés

Vous devez être connecté pour sélectionner plusieurs modèles de données, les télécharger ou les analyser.

72 Résultats de recherche.
Pertinence Commentaire Plus récent Moins récent

HIS documentation cancer conference - gynecology breast cancer - HIS

- 07/08/2013 - 1 Formulaire, 8 Groupes Item, 86 Eléments de données, 2 Langues
Groupes Item: Admininstrative Daten, Dokumentation TB Mamma, klin. TNM-Stadium, vorh. path.TNM-Stadium, TNM-Stadium der Patho, endgültiges TNM-Stadium, Geplante Therapie, Weiteres
HIS form from Soarian. "Frauenklinik Erlangen" with friendly permission of the gynecology Erlangen (Prof. Beckmann) and the medical informatics department Erlangen (PD Dr. Bürkle)

Eligibility DRKS00003516 NCT01374789 Urinary Bladder Cancer - Eligibility

- 20/09/2021 - 1 Formulaire, 2 Groupes Item, 39 Eléments de données, 2 Langues
Groupes Item: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT01374789

Bladder Cancer NCT01224665 - Pre-Randomization Off-Study Form Bladder Cancer #52060 S1011 NCT01224665

- 24/03/2015 - 1 Formulaire, 5 Groupes Item, 24 Eléments de données, 1 Langue
Groupes Item: Header Module, Treatment Information, Off Treatment Reason, Additional Treatment, Vital Status
S1011 Pre-Randomization Off-Study Form (#52060) Standard or Extended Pelvic Lymphadenectomy in Treating Patients Undergoing Surgery for Invasive Bladder Cancer NCT01224665 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=9399F2B7-7E68-06C0-E040-BB89AD436952

HIS pathology documtation cancer conference breast cancer - HIS

- 07/08/2013 - 1 Formulaire, 3 Groupes Item, 35 Eléments de données, 2 Langues
Groupes Item: Admininstrative Daten, Pathologie-Dokumentation für FK Tumorboard, Pathologische TNM-Stadium
HIS form from Soarian. "Frauenklinik Erlangen" with friendly permission of the gynecology Erlangen (Prof. Beckmann) and the medical informatics department Erlangen (PD Dr. Bürkle)

UFK HD: Gynäkologische Tumore - Anamnesis

- 13/02/2023 - 1 Formulaire, 3 Groupes Item, 45 Eléments de données, 2 Langues
Groupes Item: anamnesis_general, anamnesis_specific, WHO-5
Dieses Projekte soll an der UFK HD im Bereich der gynäkologischen Tumore (1) die strukturierte Datenerfassung gemäß CDISC Standard ermöglich und (2) die klinische Arbeit entlang des Patientinnenweges digitalisieren und zur Arbeitserleichterung für die beteiligten Mitarbeiter:innen führen. Affiliation: Department of Obstetrics and Gynecology, Heidelberg University Hospital

Eligibility DRKS00004052 NCT00661609 Bladder Cancer - Eligibility Advanced Bladder Cancer NCT00661609

- 17/09/2021 - 1 Formulaire, 2 Groupes Item, 8 Eléments de données, 1 Langue
Groupes Item: Inclusion criteria, Exclusion criteria
Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) See http://clinicaltrials.gov/ct2/show/record/NCT00661609

Eligibility DRKS00010322 NCT00246974 Bladder Cancer - Eligibility

- 11/12/2013 - 1 Formulaire, 2 Groupes Item, 7 Eléments de données, 2 Langues
Groupes Item: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00246974

dbGaP phs000942 Use of WGS for Diagnosis and Discovery in the Cancer Genetics Clinic - Eligibility

- 27/11/2024 - 5 Formulaires, 1 Groupe Item, 1 Élément de données, 1 Langue
Groupe Item: IG.elig
Principal Investigator: Theodora S. Ross, MD, PhD, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA, and Department of Cancer Genetics, UT Southwestern Medical Center, Dallas, TX, USA MeSH: Neoplasms,Breast Neoplasms,Ovarian Neoplasms,Peritoneal Neoplasms,Skin Neoplasms,Esophageal Neoplasms,Thyroid Neoplasms,Urinary Bladder Neoplasms,Endometrial Neoplasms,Fallopian Tube Neoplasms,Melanoma,Testicular Neoplasms,Bile Duct Neoplasms,Lung Neoplasms,Colonic Neoplasms,Adrenocortical Carcinoma,Carcinoma, Renal Cell,Colonic Polyps,Adenomatous Polyposis Coli,Lymphoma, Large B-Cell, Diffuse,Pheochromocytoma,Paraganglioma,Leiomyoma,Hemangioblastoma,Hyperparathyroidism,Pancreatic Neoplasms,Vulvar Neoplasms,Brain Neoplasms,Liver Neoplasms,Kidney Neoplasms,Prostatic Neoplasms,Glioblastoma,Oncocytoma, renal https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000942 Despite the potential of whole-genome sequencing (WGS) to improve patient diagnosis and care, the empirical value of WGS in the cancer genetics clinic is unknown. We performed WGS on members of two cohorts of cancer genetics patients: those with BRCA1/2 mutations (n = 176) and those without (n = 82). Initial analysis of potentially pathogenic variants (PPVs, defined as nonsynonymous variants with allele frequency 1% in ESP6500) in 163 clinically-relevant genes suggested that WGS will provide useful clinical results. This is despite the fact that a majority of PPVs were novel missense variants likely to be classified as variants of unknown significance (VUS). Furthermore, previously reported pathogenic missense variants did not always associate with their predicted diseases in our patients. This suggests that the clinical use of WGS will require large-scale efforts to consolidate WGS and patient data to improve accuracy of interpretation of rare variants. While loss-of-function (LoF) variants represented only a small fraction of PPVs, WGS identified additional cancer risk LoF PPVs in patients with known BRCA1/2 mutations and led to cancer risk diagnoses in 21% of non-BRCA cancer genetics patients after expanding our analysis to 3209 ClinVar genes. These data illustrate how WGS can be used to improve our ability to discover patients' cancer genetic risks. "Reprinted from doi:10.1016/j.ebiom.2014.12.003, with permission from EBioMedicine."

pht004834.v1.p1

1 Groupe Item 5 Eléments de données

pht004835.v1.p1

1 Groupe Item 5 Eléments de données

pht004836.v1.p1

1 Groupe Item 16 Eléments de données

pht004837.v1.p1

1 Groupe Item 5 Eléments de données

dbGaP phs000397 NIA Long Life Family Study (LLFS) - Eligibility

- 12/10/2022 - 6 Formulaires, 1 Groupe Item, 3 Eléments de données, 1 Langue
Groupe Item: IG.elig
Principal Investigator: Michael A. Province, PhD, Washington University School of Medicine, St. Louis, MO, USA MeSH: Longevity,Aging,Cardiovascular Diseases,Neoplasms,Stroke,Inflammation,Immune System,Diabetes Mellitus,Hypertension,Dyslipidemias,Lipids,Osteoporosis,Pulmonary Function Tests,Kidney Function Tests,Alzheimer Disease,Depression,Personality,Executive Function,Reproductive History https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000397 The Long Life Family Study (LLFS) is an international collaborative study of the genetics and familial components of exceptional survival, longevity, and healthy aging. Families were recruited through elderly probands (generally in their 90s) who self-reported on the survival history of their parents and siblings, and on the basis of this information, families which showed clustering of exceptional survival were recruited. [Specifically, a Family Longevity Selection Score (FLOSS) ≥7 was required. The FLOSS measures the average excess Observed lifespan over that Expected based upon lifetables, while adding a bonus term for still-living individuals. Thus FLOSS is a useful tool for scoring and selecting families for inclusion in a research study of exceptional survival (Sebastiani et al., 2009, PMID: 19910380)]. Probands resided in the catchment areas of four Field Centers (Boston University, Columbia University, University of Pittsburgh, and University of Southern Denmark). Recruited family members were phenotyped through extensive in-home visits by teams of technicians who traveled all over the USA and Denmark. Blood assays were centrally processed at a Laboratory Core (University of Minnesota) and protocols were standardized, monitored and coordinated through a Data Management Coordinating Center (Washington University). We examined and extensively phenotyped in all major domains of healthy aging, 4,953 individuals in 539 families through comprehensive in-home visits. Of these, 4,815 gave dbGaP sharing permission and had sufficient quantity/quality of DNA for GWAS genotyping. This large collection of families, selected on the basis of clustering for exceptional survival, is a unique resource for the study of human longevity and healthy aging. We estimate that less than 1% of the Framingham Heart Study (FHS) families (a roughly random population family sample) would meet the minimal entrance criteria for exceptional survival required in the LLFS (Sebastiani et al., 2009, PMID: 19910380). Thus, the least exceptional LLFS families show more clustering for exceptional longevity than 99% of the FHS families. Although the LLFS pedigrees were selected on the basis of longevity per se in the upper generation (and the generation above that), the children's generation have significantly lower rates of many major diseases and have better healthy aging profiles for many disease phenotypes (Newman et al., 2011, PMID: 21258136). The participants had their first in-person visit between 2006 and 2009. After that visit, they were contacted annually by telephone to update vital status, medical history, and general health. Between 2014 and 2017, willing participants completed a second in-person visit. The second visit followed the same protocols and centralized training as the first visit. During the second visit, a portable carotid ultrasound exam was added. Again, participants were continuously contacted annually for telephone follow-up during the period of the second in-person visit and after that. Annual telephone follow-ups currently ongoing, and plans for a third in-person visit are in progress.

pht002407.v3.p3

1 Groupe Item 4 Eléments de données

pht002408.v3.p3

1 Groupe Item 6 Eléments de données

pht002410.v3.p3

1 Groupe Item 106 Eléments de données

pht003356.v3.p3

1 Groupe Item 4 Eléments de données

pht002409.v3.p3

1 Groupe Item 3 Eléments de données

Follow-Up Form Bladder Cancer (NCT00942331)

- 08/01/2015 - 1 Formulaire, 8 Groupes Item, 44 Eléments de données, 1 Langue
Groupes Item: Header, Vital Status, Treatment Status, Disease Assessment, Measurable Disease Response, Notice of New Primary, Long-Term Toxicity, Non-Protocol Therapy
CALGB 90601: Follow-Up Form Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer NCT00942331 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=6591C082-D8C1-EC1C-E040-BB89AD43479B

Eligibility NCT00522834 Melanoma - Eligibility

- 20/09/2021 - 1 Formulaire, 2 Groupes Item, 13 Eléments de données, 2 Langues
Groupes Item: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00522834

On-Study Form Bladder Cancer NCT00014534 CALGB-90104

- 21/08/2015 - 1 Formulaire, 3 Groupes Item, 61 Eléments de données, 1 Langue
Groupes Item: Muscle Invasive Bladder Disease: Prior Treatment Affecting the Bladder, Prior Therapy Date, CCRR MODULE
On-Study Form Bladder Cancer NCT00014534 CALGB-90104 NCT00014534 NCI Cooperative Group On-Study Form-Revised (CALGB-90104) Combination Chemotherapy in Treating Patients With Bladder Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=BE1B6E9C-942E-7181-E034-0003BA12F5E7

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial